Theriva Biologics announced it has dosed its first patient in Phase 2a VIRAGE2 for VCN-01, marking the start of dosing in the trial. As an early clinical milestone for a clinical-stage company, the news is modestly positive but not yet indicative of efficacy or timelines.
Theriva Biologics announced it has dosed its first patient in Phase 2a VIRAGE2 for VCN-01, marking the start of dosing in the trial. As an early clinical milestone for a clinical-stage company, the news is modestly positive but not yet indicative of efficacy or timelines.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
